Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedisamil for Rapid Conversion of Atrial Fibrillation/Flutter
NCT00126061Phase 3Completed
- Sponsor
- Solvay
- Start
- Oct 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of tedisamil in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms), sponsored by Solvay. Primary endpoint: Conversion to Normal Sinus Rhythm at 2.5 hours. Started Oct 2004; status: completed.
02
Drugs
tedisamil
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00126061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126061.